Abstract
The efficacy of antifibrinolytic therapy in the management of acute upper gastrointestinal haemorrhage has been investigated in a double-blind clinical trial. Two-hundred patients were studied using tranexamic acid, a potent antifibrinolytic agent. Of these, 103 were in the treatment group and 97 in the control group. Patients were analysed to determine severity of initial blood loss, transfusion requirements, together with the incidence of recurrent bleeding, surgical intervention, and death. Final diagnosis as to the site of bleeding was arrived at using endoscopy, barium studies, and the findings at operation and necropsy. The groups were well matched as regards severity of initial haemorrhage, age, sex, aetiological diagnosis, and precipitating factors. A significant difference was observed in the requirement for surgical intervention to control continuing or recurrent haemorrhage. Twenty-three of 97 in the control group and seven of 103 in the treatment group required surgery.There appeared to be a reduction in the transfusion rate after the first three days of hospitalization in the treatment group. There were no significant differences in mortality or in side-effects between the two groups.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andersson L. Antifibrinolytic drugs in the treatment of urinary tract haemorrhage. Prog Surg. 1972;10:76–93. doi: 10.1159/000392836. [DOI] [PubMed] [Google Scholar]
- Andersson L., Nilsoon I. M., Colleen S., Granstrand B., Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci. 1968 Jun 28;146(2):642–658. doi: 10.1111/j.1749-6632.1968.tb20322.x. [DOI] [PubMed] [Google Scholar]
- Andersson L., Nilsson I. M., Niléhn J. E., Hedner U., Granstrand B., Melander B. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol. 1965;2(3):230–247. doi: 10.1111/j.1600-0609.1965.tb01300.x. [DOI] [PubMed] [Google Scholar]
- Callender S. T., Warner G. T., Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J. 1970 Oct 24;4(5729):214–216. doi: 10.1136/bmj.4.5729.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cormack F., Chakrabarti R. R., Jouhar A. J., Fearnley G. R. Tranexamic acid in upper gastrointestinal haemorrhage. Lancet. 1973 Jun 2;1(7814):1207–1208. doi: 10.1016/s0140-6736(73)90525-4. [DOI] [PubMed] [Google Scholar]
- Cox H. T., Poller L., Thomson J. M. Evidence for the release of gastric fibrinolytic activity into peripheral blood. Gut. 1969 May;10(5):404–407. doi: 10.1136/gut.10.5.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cox H. T., Poller L., Thomson J. M. Gastric fibrinolysis. A possible aetiological link with peptic ulcer. Lancet. 1967 Jun 17;1(7503):1300–1302. doi: 10.1016/s0140-6736(67)91594-2. [DOI] [PubMed] [Google Scholar]
- DUBBER A. H., MCNICOL G. P., DOUGLAS A. S., MELANDER B. SOME PROPERTIES OF THE ANTIFIBRINOLYTICALLY ACTIVE ISOMER OF AMINO-METHYLCYCLOHEXANE CARBOXYLIC ACID. Lancet. 1964 Dec 19;2(7373):1317–1319. doi: 10.1016/s0140-6736(64)91108-0. [DOI] [PubMed] [Google Scholar]
- Gibbs J. R., Corkill A. G. Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms. Postgrad Med J. 1971 Apr;47(546):199–200. doi: 10.1136/pgmj.47.546.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SACK E., SPAET T. H., GENTILE R. L., HUDSON P. B. Reduction of postprostatectomy bleeding by episilon-aminocaproic acid. N Engl J Med. 1962 Mar 15;266:541–543. doi: 10.1056/NEJM196203152661105. [DOI] [PubMed] [Google Scholar]
- Tovi D., Nilsson I. M., Thulin C. A. Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurol Scand. 1972;48(4):393–402. doi: 10.1111/j.1600-0404.1972.tb07561.x. [DOI] [PubMed] [Google Scholar]